Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 8 of 21 for:    "Bone Disease" | "Methylprednisolone"

Seronegative Oligoarthritis of the Knee Study (SOKS) (SOKS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01216631
Recruitment Status : Terminated (Unable to recruit)
First Posted : October 7, 2010
Results First Posted : May 13, 2016
Last Update Posted : May 13, 2016
Sponsor:
Collaborator:
Centocor, Inc.
Information provided by (Responsible Party):
Laura Coates, University of Leeds

Tracking Information
First Submitted Date  ICMJE October 6, 2010
First Posted Date  ICMJE October 7, 2010
Results First Submitted Date  ICMJE May 26, 2015
Results First Posted Date  ICMJE May 13, 2016
Last Update Posted Date May 13, 2016
Study Start Date  ICMJE September 2010
Actual Primary Completion Date August 2011   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: October 6, 2010)
Ultrasound Synovitis Score [ Time Frame: 8 weeks ]
reduction of ultrasound synovitis score of the affected knee at 8 weeks following intiation of treatment
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT01216631 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: October 6, 2010)
  • US Synovitis Score [ Time Frame: 2 weeks ]
    Change in US synovitis score of the affected knee at 2 and 8 weeks after treatment initiation
  • Pain Visual Analogue Scale [ Time Frame: 2 weeks ]
    Change in patient's assessment of pain by a 100mm visual analogue score
  • Psoriatic Arthritis Quality of Life Scale (PsQOL) [ Time Frame: 2 weeks ]
    Change in PsQOL score from baseline
  • Rheumatoid Arthritis Outcome Score (RAOS) [ Time Frame: 2 weeks ]
    Change in RAOS questionnaire score
  • US Synovitis Score [ Time Frame: 16 weeks ]
    Change in US synovitis score of the affected knee at 2 and 8 weeks after treatment initiation
  • Pain Visual Analogue Scale [ Time Frame: 6 weeks ]
    Change in patient's assessment of pain by a 100mm visual analogue score
  • Pain Visual Analogue Scale [ Time Frame: 8 weeks ]
    Change in patient's assessment of pain by a 100mm visual analogue score
  • Pain Visual Analogue Scale [ Time Frame: 14 weeks ]
    Change in patient's assessment of pain by a 100mm visual analogue score
  • Pain Visual Analogue Scale [ Time Frame: 16 weeks ]
    Change in patient's assessment of pain by a 100mm visual analogue score
  • Psoriatic Arthritis Quality of Life Scale (PsQOL) [ Time Frame: 26 weeks ]
    Change in PsQOL score from baseline
  • Psoriatic Arthritis Quality of Life Scale (PsQOL) [ Time Frame: 6 weeks ]
    Change in PsQOL score from baseline
  • Psoriatic Arthritis Quality of Life Scale (PsQOL) [ Time Frame: 8 weeks ]
    Change in PsQOL score from baseline
  • Psoriatic Arthritis Quality of Life Scale (PsQOL) [ Time Frame: 14 weeks ]
    Change in PsQOL score from baseline
  • Psoriatic Arthritis Quality of Life Scale (PsQOL) [ Time Frame: 16 weeks ]
    Change in PsQOL score from baseline
  • Rheumatoid Arthritis Outcome Score (RAOS) [ Time Frame: 6 weeks ]
    Change in RAOS questionnaire score
  • Rheumatoid Arthritis Outcome Score (RAOS) [ Time Frame: 8 weeks ]
    Change in RAOS questionnaire score
  • Rheumatoid Arthritis Outcome Score (RAOS) [ Time Frame: 14 weeks ]
    Change in RAOS questionnaire score
  • Rheumatoid Arthritis Outcome Score (RAOS) [ Time Frame: 16 weeks ]
    Change in RAOS questionnaire score
  • Rheumatoid Arthritis Outcome Score (RAOS) [ Time Frame: 26 weeks ]
    Change in RAOS questionnaire score
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Seronegative Oligoarthritis of the Knee Study (SOKS)
Official Title  ICMJE Intra-articular and Intravenous Infliximab in the Treatment of Resistant Seronegative Oligoarthritis of the Knee
Brief Summary The aim of this study is to establish the efficacy and duration of effect of intra-articular (IA) infliximab vs intravenous infliximab vs current standard care (IA steroid injections) in seronegative oligoarthritis. All patients will have seronegative arthritis affecting less than 5 joints but including at least one knee. 10 patients will receive IA infliximab injections to the affected knee, 10 will receive IA steroid injections to the affected knee and 10 will receive a course of intravenous infliximab. Patients will not be aware of their group as this is a placebo-controlled study.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Spondylarthropathies
Intervention  ICMJE
  • Drug: methylprednisolone
    intra-articular injection of methylprednisolone (80mg given at baseline only)
    Other Name: depomedrone
  • Drug: Infliximab
    intra-articular injection of 100mg infliximab given at baseline only
    Other Name: remicade
  • Drug: Infliximab
    intravenous infliximab at a dose of 5mg/kg (as per patient weight) given at week 0, 2, 6 and 14
    Other Name: remicade
Study Arms  ICMJE
  • Active Comparator: IA steroid
    Intra-articular injection of steroid (80mg depomedrone)
    Intervention: Drug: methylprednisolone
  • Experimental: IA infliximab
    intra-articular injection of 100mg infliximab
    Intervention: Drug: Infliximab
  • Experimental: IV infliximab
    intravenous infusions of infliximab given at 0, 2, 6 and 14 weeks at a dose of 5mg/kg (patient body weight)
    Intervention: Drug: Infliximab
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: May 10, 2016)
1
Original Estimated Enrollment  ICMJE
 (submitted: October 6, 2010)
30
Actual Study Completion Date  ICMJE August 2011
Actual Primary Completion Date August 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Inflammatory oligoarthritis (4 or less active joints) with at least one swollen knee joint of at least 3 months duration
  • Rheumatoid factor and anti-CCP Ab negative
  • Either arthritis onset at <45 years of age, or arthritis onset at ≥45 years of age with early morning stiffness>30mins or raised inflammatory markers
  • If under 40 years of age, clinical exclusion of a diagnosis of gout.
  • If 40 years or older at screening, a prior normal examination of synovial fluid from the affected joint excluding crystal arthropathy or infection.
  • Failure of methotrexate (inefficacy after >3 month trial, intolerance or contra-indication)
  • Have the capacity to understand and sign an informed consent form.
  • Gender: male or female
  • 18 years of age or over.
  • Women must be either postmenopausal (no menstrual period for a minimum of 1 year) or surgically sterilized or in use of adequate birth control measures and have a negative serum pregnancy test on entry in the study.
  • Men and women of childbearing potential must use adequate birth control measures (e.g., abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, implantable or injectable contraceptives or surgical sterilization) for the duration of the study and should continue such precautions for 6 months after receiving the last infusion.
  • Are considered eligible according to the tuberculosis (TB) eligibility assessment, screening, and early detection of reactivation rules defined in the protocol
  • The screening laboratory test results must meet the following criteria

    • WBC (white blood cell count): >3.5 x 109/L
    • ANC (absolute neutrophil count): >1.5 x 109/L
    • Hemoglobin: >10g/dL
    • Platelets: >120 x 109/L
    • SGPT (ALT - alanine aminotransferase) < 1.5 times upper normal limit (i.e. 60iu/L)
  • Have no history of latent or active TB prior to screening. An exception is made for subjects with a history of latent TB and documentation of having completed appropriate treatment for latent TB (see Appendix 3) within 3 years prior to the first administration of study agent. It is the responsibility of the investigator to verify the adequacy of previous anti-tuberculous treatment and provide appropriate documentation.
  • Have no signs or symptoms suggestive of active TB upon medical history and/or physical examination.
  • Have had no recent close contact with a person with active TB or, if there has been such contact, will be referred to a physician specializing in TB to undergo additional evaluation and, if warranted, receive appropriate treatment for latent TB prior to the first administration of study agent.
  • Within 6 weeks prior to the first administration of study agent, either have a negative QuantiFeron test result (see Appendix 3) or have a newly identified positive QuantiFeron test result during screening in which active TB has been ruled out and for which appropriate treatment for latent TB has been initiated prior to the first administration of study agent.
  • Have a chest radiograph (posterior-anterior view and if required, a lateral view), taken within 3 months prior to the first administration of study agent and read by a qualified radiologist, with no evidence of current, active TB or old, inactive TB.

Exclusion Criteria:

  • Grade 4 osteoarthritis (Kellgren-Lawrence score) on plain radiograph of the knee
  • Rheumatoid Arthritis (defined by the ACR criteria for the diagnosis of RA, 1987)
  • Ankylosing Spondylitis (defined by the modified New York Criteria)
  • Clinical diagnosis of gout or previous evidence of crystal arthropathy on synovial fluid aspirates
  • Women who are pregnant, nursing, or planning pregnancy within 6 months after the last infusion (this includes father's who plan on fathering a child within 6 months after their last infusion).
  • Have had any previous treatment with biological therapies.
  • History of receiving human/murine recombinant products or a known allergy to murine products. A known allergy to murine product is definitely an exclusion criterion
  • Previous intra-muscular, intra-articular or intra-venous steroids within 4 weeks prior to baseline.
  • Previous oral steroids at a dose >10mg/day prednisolone or equivalent for 4 weeks prior to baseline.
  • Documentation of seropositive for human immunodeficiency virus (HIV).
  • Documentation of a positive test for hepatitis B surface antigen or hepatitis C.
  • Have a history of alcohol or substance abuse within the preceding 6 months that, in the opinion of the investigator, may increase the risks associated with study participation or study agent administration, or may interfere with interpretation of results.
  • Have a known history of serious infections (e.g., hepatitis, pneumonia, or pyelonephritis) in the previous 3 months.
  • Have or have had an opportunistic infection (e.g., herpes zoster [shingles], cytomegalovirus, Pneumocystis carinii, aspergillosis, histoplasmosis, or mycobacteria other than TB) within 6 months prior to screening
  • Have had a Bacille Calmette-Guérin (BCG) vaccination within 12 months of screening.
  • Are considered ineligible according to the TB eligibility assessment, screening, and early detection of reactivation rules described in Appendix 3.
  • Have a chest radiograph within 3 months prior to the first administration of study agent that shows an abnormality suggestive of a malignancy or current active infection.
  • Have a history of lymphoproliferative disease, including lymphoma or signs suggestive of possible lymphoproliferative disease such as lymphadenopathy of unusual size or location (e.g., nodes in the posterior triangle of the neck, infraclavicular, epitrochlear, or periaortic area), or splenomegaly.
  • Currently have any known malignancy other than the condition being treated or have a history of malignancy, with the exception of basal cell or squamous cell carcinoma of the skin that has been fully excised with no evidence of recurrence.
  • Have current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, or cerebral disease.
  • Are unable or unwilling to undergo multiple venipunctures because of poor tolerability or lack of easy access.
  • Use of any investigational drug within 30 days prior to screening or within 5 half-lives of the investigational agent, whichever is longer.
  • Presence of a transplanted solid organ (with the exception of a corneal transplant > 3 months prior to screening).
  • Have a concomitant diagnosis or history of congestive heart failure.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United Kingdom
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01216631
Other Study ID Numbers  ICMJE 2009-015810-23
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Laura Coates, University of Leeds
Study Sponsor  ICMJE University of Leeds
Collaborators  ICMJE Centocor, Inc.
Investigators  ICMJE
Principal Investigator: Philip G Conaghan, FRCP University of Leeds
PRS Account University of Leeds
Verification Date May 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP